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1. Introduction
At the present time, pathological examination of a liver fragment obtained by liver biopsy
remains an essential diagnostic tool of numerous chronic liver diseases [1] Indications for
liver biopsy (LB) have changed considerably over recent years due to the development of
sensitive and specific tests for diagnosis of several chronic liver diseases (i.e., serology for
hepatitis  C,  antimitochondrial  M2 in  primary biliary  cirrhosis,  genetic  screening for  he‐
reditary hemochromatosis), but also because of intensive development during the last dec‐
ade  of  non-invasive  assessment  of  fibrosis  using  serum tests  (FibroTest®,  FibroMeter®,
APRI  score)  and/or  by  physical  methods  such  as  pulsed  elastography  (FibroScan®),  in
particular, for chronic hepatitis C. Ultrasound-guided liver biopsy is often necessary to ob‐
tain a tumor fragment in cases of suspected primary or secondary liver malignancy and
will not be discussed here [1]. In the present article, we will limit ourselves to indications
of  liver  biopsy in diffuse parenchymal disease of  the liver  and its  relative and absolute
contraindications.  Modalities  for  performing  liver  biopsy  and complications  will  not  be
discussed here.  Liver biopsy is  an invasive procedure with possible complications;  thus,
individual benefits for the patient must be weighed against possible risks. Liver biopsy is
indicated when the expected amount of information obtained exceeds the risks related to
the  procedure,  when  the  diagnosis  required  for  establishing  a  prognosis  cannot  be  ob‐
tained without pathological examination of the liver, and finally, when the treatment deci‐
sion depends on pathological results [1].
© 2012 Cadranel and Nousbaum; licensee InTech. This is an open access article distributed under the terms of
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2. Indications for LB
Indications for liver biopsy in chronic liver disease have evolved (Tables 1,2). The main ad‐
vantages of LB with respect to the etiology of liver disease are shown in Table 2 and will be
detailed later. The indication for liver biopsy is appropriate when the treatment or prognosis
will be modified by results of histopathological examination of the liver. However, liver bi‐
opsy is not appropriate when the therapeutic decision and/or establishment of a diagnosis
does not depend on histological findings [1].
Indications
For diagnostic purposes - Combination of several parenchymal liver diseases  - Abnormal liver tests of unknown origin *.
- Fever of unknown origin.
- Focal or diffuse abnormalities on imaging studies.
For prognostic purposes - Assessment of known parenchymal liver diseases.
For research purposes - Development of treatments related to results of histological analysis
* After complete check-up, according to (2)
Table 1. Indications for liver biopsy
Cause of liver disease Diagnosis Evaluation of
fibrosis
Prognosis Management
Hepatitis B - +++ + (+) +++




Hemochromatosis +/- +++ + (+) +
Wilson's disease ++ +++ + -




+++ +++ + ++++
Primary biliary cirrhosis / overlap
syndrome
++ +++ +++ ++
Primary sclerosing cholangitis ++ +/0 0 +
Alcoholic liver disease +/- ++ ++ +
Severe acute alcoholic hepatitis +++ NA NA +
Steatosis / steatohepatitis +++ +++ + +
Infiltrative lesions of the liver ++++ NA NA +
Medicinal cause ++ NA NA +
Follow-up after liver transplantation ++++ +++ + +
NA: not applicable
Table 2. Utility of liver biopsy in clinical practice for diffuse parenchymal damage
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Etiology 1997 Study  [31]
of 2,084 biopsies
(%)
2009 Study  [13]
of 8,580 biopsies
(%)
Hepatitis C 54.1 33.6
Delta hepatitis B 5.8 14.4
Hereditary hemochromatosis 4.3 1
Cholestatic disease of the




Autoimmune hepatitis 1 3.5
Liver transplantation 3 12.
Miscellaneous 17.6 12.2
Metabolic steatopathy unlisted 8.9
Table 3. Indications for liver biopsy. Evolutionary trend in France.
2.1. Chronic hepatitis C
Liver biopsy has long been the only reference for assessing necroinflammatory lesions and
fibrosis in hepatitis C. Liver biopsy is most useful for evaluating the existence of co-morbidi‐
ties: alcoholic liver disease, non alcoholic fatty liver disease and iron overload, which are es‐
pecially common in patients with chronic hepatitis C. In 2002, the French consensus
conference no longer recommended systematic liver biopsy in patients with consistently
normal transaminases [2]. At that time, for patients recently contaminated with genotype 2
or 3 infection, without co-morbidity and/or when the indication was viral eradication inde‐
pendently of fibrosis data, then antiviral treatment could be undertaken without requiring
LB [2]. Furthermore, liver biopsy is not useful when diagnosis of cirrhosis is obvious [2].
While abdominal ultrasonography is satisfactory for assessing the existence of steatosis, liv‐
er biopsy is needed in order to evaluate the existence of steatohepatitis, iron overload or al‐
coholic liver disease associated with hepatitis C. Such lesions are associated with more rapid
fibrosis progression and a less favorable response to treatment. The major development over
the last ten years, spurred by French teams, of non-invasive assessment of fibrosis during
the course of hepatitis C has significantly reduced indications for liver biopsy in patients
with chronic hepatitis C. Several serum tests (FibroTest®, FibroMeter®, Hepascore®) are
currently being validated by the French High Authority of Health for establishing extent of
fibrosis in patients with untreated chronic hepatitis C and no co-morbidity [3-5]. The FibroT‐
est has been validated by numerous studies and several independent teams [6]. The FibroM‐
eter ® virus [9] has also been the subject of independent validations by different teams.
FibroScan ® is useful for confirming or ruling out the presence of cirrhosis [7, 8], and for
patients with HIV-HCV co-infection. In a recent survey, the use of liver biopsy was reduced
by 50 % for chronic hepatitis C patients [9]. Most hepatologists in France no longer recom‐
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mend first-line liver biopsy for chronic hepatitis C (Table 4). Discrepancy between results of
serum fibrosis markers and FibroScan®, when performed simultaneously, is an indication
for liver biopsy.
Transparietal liver biopsy Transjugular liver biopsy
Absolute contraindications: 
Absence of patient cooperation
Clotting abnormalities (see text)
Need to maintain anticoagulants or antiplatelets
Vascular lesion along the puncture route










Infection of the right pleural cavity
Table 4. Contraindications to transjugular and transparietal liver biopsy
2.2. Hepatitis B and hepatitis B-delta
Serum markers of non-invasive necroinflammatory lesions and fibrosis in hepatitis B and B-
delta have not been fully validated, nor has the FibroScan [10, 11]. Scientific institutions rec‐
ommend that liver biopsy be performed prior to any treatment decision in the context of
chronic hepatitis B or B-delta. Liver biopsy is the best means of assessing necroinflammatory
lesions and fibrosis in chronic hepatitis B [12]. The evolutionary trend in indications for liver
biopsy for hepatitis C and B has been inverted over the last twelve years: the number of liver
biopsies for hepatitis C in 2009 represented 33.6%, compared to 54.1% in 1997, this trend be‐
ing related to development of non-invasive measures for assessing fibrosis; however, the
number of liver biopsies for hepatitis B and delta-B has tripled in France [13] (Table 4). This
is probably related to the increased number of patients with hepatitis B in France and the
emergence of more effective treatment, along with insufficient validation of non-invasive
fibrosis assessment methods.
2.3. Alcoholic liver disease
Liver biopsy remains essential in case of severe acute alcoholic hepatitis with Maddrey func‐
tion above 32. In this situation, lesions of acute alcoholic hepatitis are absent in 20% of cases
[14], while the benefit of corticosteroids in the absence of alcoholic hepatitis lesions has not
been demonstrated with an increased risk of bacterial infection. However, this point has
been debated by some authors [15]. When there are no signs of severe acute alcoholic hepati‐
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tis and if extensive fibrosis or cirrhosis is suspected, then the Fibrotest® [16]and FibroScan®
[17] give satisfactory diagnostic performances.
2.4. Non alcoholic fatty liver disease
In patients with hepatic steatosis as part of the metabolic syndrome, liver biopsy is useful
for differentiating fatty lesions from steatohepatitis (NASH), the evolutionary potential of
which is much more severe (risk of cirrhosis and hepatocellular carcinoma ). The presence of
body mass index > 30 kg/m², AST/ALT ratio > 1, hypertriglyceridemia > 1.7 mmol/L, age > 50
years and a syndrome of insulin resistance are predictors of steatohepatitis and fibrotic le‐
sions. When elements of metabolic syndrome exist with or without steatosis visualized on
ultrasonography, then LB performed for what is referred to as “unexplained" cytolysis leads
to a diagnosis of steatosis and steatohepatitis lesions in 60% of the cases [18]. Liver biopsy
enables accurate diagnosis of lesions and evaluation of the degree of fibrosis [1]. It should be
noted, however, that in this setting, steatosis FibroMeter ® [19] and Fibromax® [20] can pro‐
vide evidence of the existence of fibrosis and can predict the existence of NASH.
2.5. Cholestatic liver diseases, and autoimmune diseases of the liver
Diagnosis of primary biliary cirrhosis is based on identification of cholestasis associated
with antimitochondrial M2 antibodies. Liver biopsy is not useful for diagnosis of primary
biliary cirrhosis [21], but is very useful for assessing the activity and extent of fibrotic le‐
sions. FibroScan® in this indication can assess the presence or absence of cirrhosis [22]. Liver
biopsy is useful in case of a poor response to ursodeoxycholic acid and/or in case of a drastic
increase of transaminases. Liver biopsy is able to reveal moderate to severe lymphocytic
piecemeal necrosis that may fit into the context of overlap syndrome, requiring a change in
therapy and the addition of corticosteroids. During the course of autoimmune hepatitis [1,
23] , liver biopsy is necessary to assess piecemeal necrotic lesions and fibrosis stage. It is es‐
pecially helpful in the absence of antibodies. In autoimmune hepatitis, no method of non-
invasive evaluation of fibrosis has been developed. Liver biopsy is also necessary prior to
discontinuation of immunosuppressive therapy, since the presence of histological piecemeal
necrotic lesions is associated with almost constant recurrence of outbreaks of cytolysis dele‐
terious to the liver [24]. When confronted with possible chronic cholestasis, the diagnosis of
primary sclerosing cholangitis is based on data from the magnetic resonance cholangiopan‐
creatography (MRCP)[21]. Liver biopsy often confirms the diagnosis, but can appear normal
in 25% of the cases. When MRCP is normal, liver biopsy enables diagnosis of cholangitis of
small bile ducts and, in all cases, helps to clarify lesions due to hepatic fibrosis [1, 21].
2.6. Genetic hemochromatosis
Diagnosis of hereditary HFE-gene-related hemochromatosis is based on the association of
hyperferritinemia with elevated saturation of transferrin and presence of the C282Y muta‐
tion in the homozygous state. Thus, liver biopsy is not mandatory for diagnosis. It is still
indicated, however, when serum ferritin is higher than 1,000 µg/L, and/or when the AST
are increased and/or if hepatomegaly is present [25].  Simple markers (platelet count and
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transaminases, possibly combined with the dosage of hyaluronic acid and/or use of Fibro‐
Scan) can indicate the existence or absence of extensive fibrosis and help to guide indica‐
tions for liver biopsy.
2.7. Unexplained abnormal liver tests
Liver biopsy is often proposed in case of unexplained abnormal liver tests, when physical
examination, biochemical and serological tests, imaging investigation could not establish a
diagnosis. In one study including 354 patients, non alcoholic fatty liver disease was the defi‐
nite diagnosis in 64 % of the cases. Other lesions included drug induced liver injury, alcohol-
related liver disease, auto-immune hepatitis, primary sclerosing cholangitis,primary and
secondary biliary cirrhosis, hemochromatosis, amyloid and glycogen storage disease, and
cryptogenic hepatitis [26]. In another study including 272 patients, NAFLD represented 59.5
% of the cases [18].
2.8. Other indications (Table 3)
Liver biopsy is essential for the diagnosis of rare diseases of the liver such as Wilson's dis‐
ease,  wherein  the  hepatic  copper  concentration  has  to  be  measured,  a  deficiency  in  al‐
pha-1 antitrypsin with evidence of PAS-positive cells, overload diseases such as Gaucher’s
disease, and amyloidosis, when there exists no other alternative [2]. In case of amyloido‐
sis, liver biopsy should be performed via the transjugular route, since there is a major risk
of bleeding in case of LBP performed via the transparietal route. Liver biopsy also helps
in diagnosing rare diseases (nodular regenerative hyperplasia, congenital hepatic fibrosis)
in  case of  prolonged abnormal  liver  function tests  [1].  In  case of  severe  acute  hepatitis,
emergency liver biopsy performed via the transjugular  route may be particularly useful
for diagnosing seronegative autoimmune hepatitis, infiltrative lesions of the liver, hepati‐
tis or herpes [1]. Liver biopsy is essential for diagnosis of abnormalities in liver function
tests when monitoring patients after liver transplantation in order to give a positive differ‐
ential diagnosis of the following anomalies: rejection, infection, drug-induced liver injury,
bile duct injury and viral reinfection. In case of hepatitis  C virus recurrence in the liver
transplant, liver biopsy is indicated; however, the FibroScan® is currently being assessed
for evaluating damage from hepatic fibrosis. In case of suspected drug-induced hepatitis,
liver biopsy may be useful if biochemical abnormalities persist beyond 3 months after ces‐
sation of  treatment or if  there is  evidence suggesting injury to the bile  ducts,  such as a
prolonged cholestatic syndrome.
It is essential that the pathologist be provided with relevant and complete clinical and bio‐
logical information. Such information should be available before performing liver biopsy in
suspected cases of rare diseases of the liver, or when bacteriological seeding or special stain‐
ing has to be performed [1], so that the fresh liver fragment is immediately transmitted to
the pathology or microbiology laboratory.
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3. Limitations
Liver biopsy has remained the “gold standard” for years. However, it is imperfect since a large
biopsy is required to make an accurate assessment of fibrotic stage and inflammatory grade.
Pathologists estimated that a 25 mm-long fragment obtained with a 16-G needle was necessary
to accurately determine the grade of chronic liver disease [27]. Colloredo et al. showed that
eleven to fifteen complete portal tracts was the minimal number below which disease stage
was significantly underestimated [28]. In a large review of the literature including 10,027 LB,
Cholongitas et al. showed that the mean ± SD length was 17.7±5.8 mm and the mean ± SD num‐
ber of portal tract was 7.5±5.8 [29]. This implies that at least two passes would be necessary to
obtain a 2.5 cm long specimen, thus potentially increasing the risk of complications.
4. Optimal methods for carrying out lb in 2012
Methods for performing LB will not be detailed here, but are available in practical guide‐
lines [30]. Several issues will be addressed:
When all conditions are met, then "ambulatory" liver biopsy may be performed [30]. In the
study published in 2000 (completed in 1997) [31], 27% of liver biopsies were performed on
an outpatient basis, most often for chronic hepatitis C; this figure is currently at 45% [13].
Several French teams have shown that outpatient liver biopsy is a safe and effective proce‐
dure and that liver biopsy performed on an outpatient basis reduces discomfort and increas‐
es the acceptability of subsequent examination conducted under the same conditions. If all
conditions are not met and/or if organizational arrangements do not permit it, then liver bi‐
opsy should be performed via traditional hospitalization.
LB is carried out by hepatogastroenterologists, radiologists and occasionally by surgeons.
Currently, liver biopsy is performed in France by a hepatogastroenterologist in 63.5% of cas‐
es, by a radiologist in 34.8% of cases and by a surgeon in 1.7% of cases [13]. The increasing
number of liver biopsies performed by radiologists in France is linked to an increased num‐
ber of biopsies performed using ultrasound guidance or guided real-time ultrasonography
[30] and by the development of the transvenous route as compared to the transparietal
route. Indeed, in 1997, 9% of liver biopsies were performed via the transvenous route com‐
pared to 22.4% in 2009 [13]. In the US, 50% of biopsies are performed by radiologists. In that
country, it is felt that the number of LB performed in order to gain sufficient expertise is at
least 40, carried out in the presence of an experienced radiologist [1].
5. Absolute and relative contraindications for LB
Absolute and relative contraindications for LB depend on the surgical approach recom‐
mended. Contraindications for liver biopsy using the transjugular or transparietal route [1,
30] are summarized in Table 4.
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5.1. Lack of patient cooperation
Absence of patient cooperation is an absolute contraindication for transparietal LB. Indeed, in
case of uncontrolled respiratory movements or agitation of the patient, the biopsy needle may
cause a tear in the liver capsule, bleeding or a pneumothorax. If the patient is unable to main‐
tain breath holding, or in the absence of expected cooperation, the question of the appropriate‐
ness of the indication for liver biopsy must be raised. If this indication is maintained, then liver
biopsy under general anesthesia might be necessary, eventually via the transvenous route.
5.2. Hemostasis disorders, history of unexplained bleeding, hemostatic disease
It is recommended that transparietal liver biopsy should not be performed if the prothrombin
rate is less than 50%, the platelet count is below 50 Giga/L or 60 Giga/L, if activated partial
thromboplastine time is greater than 1.5-fold that of the control or when bleeding time is
lengthened. The need for maintaining an anticoagulant or an antiplatelet is also a contraindica‐
tion to transparietal LB. Likewise, the existence along the puncture route of a hemangioma or a
vascular tumor is a contraindication for liver biopsy without real-time guidance. In this case,
ultrasound-guided liver biopsy may eventually be used [1]. For patients with hemophilia,
transvenous liver biopsy can be performed safely after correction of anomalies. In this indica‐
tion, non-invasive blood markers of fibrosis and FibroScan® are particularly useful.
5.3. Impossibility of carrying out liver detection
The incapacity to detect the liver by percussion or ultrasound is an absolute contraindication
to performing transparietal liver biopsy, as is suspicion of hydatid cyst.
5.4. Dilatation of extrahepatic or cholangitic bile ducts
Dilatation of the extrahepatic bile ducts and cholangitis are contraindications to transparie‐
tal liver biopsy [1].
5.5. Relative contraindications
Morbid obesity, severe ascites persisting after evacuation and infection of the right pleural
cavity are contraindications for transparietal liver biopsy [1]. The transvenous route can be
used in all these settings, and especially in case of significant ascites, morbid obesity, vascu‐
lar liver, anticoagulant or antiplatelet treatment that cannot be stopped, hemodialysis,
chronic renal failure or suspicion of amyloidosis when liver biopsy is necessary. Contraindi‐
cations for the transvenous route include bacterial cholangitis, hydatic cyst and uncorrected
deficits in hemostasis [1, 30].
6. Reducing the risk of complications
Compliance with absolute and relative contraindications for liver biopsy should lead to a
decrease in serious accidents due to LB, the presentation of which is beyond the scope of this
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paper. Liver biopsy is an invasive procedure with the possible risk of severe complications,
approximately 0.5/1,000 [1, 30]. Liver biopsy is a procedure for which there exists residual
mortality [32]. Although serious complications have decreased over time, mortality after
performing transparietal liver biopsy remains at 0.2% and deaths related to liver biopsy for
diffuse parenchymal liver amount to 1 out of 10,000 LB [32].This risk, however, has de‐
creased dramatically over time because of improvement in indications for liver biopsy and
compliance with contraindications [32].
7. Conclusion
Liver biopsy remains useful for making an etiological diagnosis and a prognostic evaluation
of many non-viral liver diseases, particularly in the context of autoimmune liver diseases, as
well as for monitoring liver transplant patients. Liver biopsy is of great value in cases of sev‐
eral associated parenchymal diseases, so as to determine the extent of each, especially in
hepatitis C. However, within the setting of isolated hepatitis C without co-morbidity, we
feel that first-line LB is no longer appropriate.
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